logo

Passion for Innovation. Compassion for Patients.™

Daiichi Sankyo UK Ltd.

UK Products

Daiichi Sankyo's products treat and prevent serious illnesses as well as help people to live longer and have healthier lives. While maintaining its portfolio of marketed pharmaceuticals for acute coronary syndromes and atrial fibrillation, Daiichi Sankyo is engaged in the development of treatments focused on the discovery of novel oncology therapies.

Listed below in alphabetic order are the brand names of Daiichi Sankyo UK key products.

Medical professionals can obtain more detailed information on our products by contacting the Medical Services department on medinfo@daiichi-sankyo.co.uk or on 0800 0285122. 

TrademarkSubstanceIndication
EfientPrasugrelAtherothrombotic events
LixianaEdoxabanStroke prevention / VTE treatment and prevention
SevikarOlmesartan + AmlodipineHypertension
Sevikar HCTOlmesartan + Amlodipine + HydrochlorotiazideHypertension
OlmetecOlmesartanHypertension
Olmetec PlusOlmesartan + HydrochlorotiazideHypertension
EvistaRaloxifeneOsteoporosis
MotifeneDiclofenac sodiumPain relief

If you experience any adverse effects whilst taking a Daiichi Sankyo product, please report the event to:

Medical Department
Daiichi Sankyo UK Limited
Chiltern Place
Chalfont Park, Gerrards Cross
SL9 0BG
0800 0285122
Email: medinfo@daiichi-sankyo.co.uk

Information on the reporting of adverse events can be obtained from www.yellowcard.gov.uk.

If you have a question about your medicine, or you are worried about your health, please speak to your doctor or pharmacist. Your doctor or pharmacist is in the best position to help you as they know your medical history.
If your doctor or pharmacist would like additional information on any Daiichi Sankyo product, we will be happy to send the information directly to them on request.

Edoxaban

Atrial Fibrillation (AF) is the most common heart rhythm disturbance encountered by doctors. It can affect adults of any age, but it is more common as people get older. In the over 65 year old age group, it affects about 10% of people. The most worrying consequence of AF is stroke.

A pulmonary embolism (PE) is a blood clot in the lung. It usually comes from smaller vessels in the leg. Clots forming in the legs are called deep vein thrombosis (DVT). DVTs and PEs are a major public health problem throughout the world and contributes significantly to morbidity and mortality in all populations, especially among patients hospitalised for acute medical and surgical illness.

Edoxaban is a blood thinner that can be used in patients with Atrial Fibrillation to prevent strokes. It can also be used for the treatment and prevention of blood clots in the legs and the lungs.

For more information please go to

http://www.atrialfibrillation.org.uk

http://www.anticoagulationeurope.org

Prasugrel

Prasugrel helps keep blood platelets from clumping together and developing a blockage in an artery.

The European Commission granted marketing authorization for prasugrel for the prevention of atherothrombotic events in patients with ACS undergoing percutaneous coronary intervention (PCI). Acute coronary syndrome includes heart attacks and unstable angina (chest pain). Coronary heart disease, which can result in ACS, is the single most common cause of death in the European Union.

Heart attack is a major manifestation of coronary heart disease, which occurs when the arteries become narrowed or clogged by cholesterol and fat deposits. In some cases the plaque can rupture, resulting in a blood clot, which may partially or totally block the blood supply to portions of the heart, resulting in ACS. Many ACS patients undergo PCI to re-open the artery, which usually includes a stent placement.